Philadelphia, PA (September 1, 2004) — GlaxoSmithKline (NYSE: GSK) announced today that it has posted the first set of data on the GSK Clinical Trial Register, a Web site that facilitates access to information derived from GSK-sponsored clinical trials.
The Register provides summary results of GSK-sponsored trials of GSK marketed medicines. It also notes references to related publications that have appeared in the medical literature.
"The Register supplements our efforts to ease access to clinical-trial data for everyone interested in medical research and patient care," said Dr. Tadataka Yamada, chairman, Research & Development, GSK. "It is important to emphasize, however, that prescribing information approved by regulatory agencies must continue to direct the appropriate use of our medicines."
The first clinical-trial summaries to be posted on the Register concern Avandia (rosiglitazone maleate), a medicine for type 2 diabetes. Additional information about trials of Avandia and other GSK medicines will be posted as the data are summarized and put into the Register format. The data are presented according to criteria that apply consistently across wide-ranging studies and ensure that the summaries are scientific and non-promotional.
Access to the Register (http://ctr.gsk.co.uk) is unrestricted.
GSK will continue to communicate clinical-trial information through journals, scientific meetings, and letters to healthcare professionals.
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies. For more information on GlaxoSmithKline visit www.gsk.com.
US Media inquiries:
Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patty Seif (215) 751 7709
UK Media inquiries:
Martin Sutton 020 8047 5502
Chris Hunter-Ward 020 8047 5502
David Mawdsley 020 8047 5502
US Analyst/Investor inquiries:
Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
European Analyst/Investor inquiries:
Duncan Learmouth 020 8047 5540
Philip Thomson 020 8047 5543
Anita Kidgell 020 8047 5542
